Marshall Wace’s ProKidney PROK Stock Holding History

Marshall Wace’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.81M	Buy	1,011,744 +399,259	+65%	+$847K	﹤0.01%	1842
2025 Q4	$1.37M	Buy	612,485 +531,279	+654%	+$1.4M	﹤0.01%	1776
2025 Q3	$197K	Sell	81,206 -383,606	-83%	-$1.02M	﹤0.01%	2576
2025 Q2	$274K	Buy	+464,812	New	+$362K	﹤0.01%	2355
2024 Q3	–	Sell	-50,242	Closed	-$124K	–	2868
2024 Q2	$124K	Buy	+50,242	New	+$135K	﹤0.01%	2385
2024 Q1	–	Sell	-23,300	Closed	-$41.5K	–	2735
2023 Q4	$41.5K	Buy	+23,300	New	+$50K	﹤0.01%	2083
2022 Q3	–	Sell	-736,968	Closed	-$7.33M	–	3702
2022 Q2	$7.33M	Buy	736,968 +548,027	+290%	+$5.42M	0.02%	1085
2022 Q1	$1.86M	Buy	188,941 +135,913	+256%	+$1.34M	﹤0.01%	2106
2021 Q4	$524K	Hold	53,028	–	–	﹤0.01%	2770
2021 Q3	$520K	Buy	53,028 +3,028	+6%	+$29.8K	﹤0.01%	2366
2021 Q2	$507K	Buy	+50,000	New	+$506K	﹤0.01%	2117

Other funds holding PROK

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

AGP

Artia Global Partners Miami, Florida $499M AUM 186.05% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace's PROK Position: Q1 2026 in Review

Marshall Wace increased its ProKidney (PROK) stake by 65% in Q1 2026, buying an estimated $847K and bringing the position to 1,011,744 shares worth $1.81M. The position accounts for ﹤0.01% of the portfolio, ranked #1842.

Marshall Wace first reported a position in PROK in Q2 2021 and has held it in 11 quarters since. The position peaked at $7.33M in Q2 2022. 71 funds tracked by Wall St. Rank hold PROK as of Q1 2026.

Marshall Wace held 1,011,744 shares of ProKidney worth $1.81M as of Q1 2026.
Marshall Wace bought 399,259 ProKidney shares in Q1 2026, an estimated $847K.
ProKidney made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1842 holding.
Marshall Wace first reported a position in ProKidney in Q2 2021 and has held it in 11 quarters since.
Marshall Wace's ProKidney position peaked at $7.33M in Q2 2022.
71 funds tracked by Wall St. Rank held ProKidney as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.